Low-grade Glioma

Oncology
7
Pipeline Programs
5
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
6100%
+ 2 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

One Biosciences
One BiosciencesFrance - Paris
4 programs
1
1
1
TovorafenibPhase 3Small Molecule1 trial
TovorafenibPhase 2Small Molecule1 trial
DAY101Phase 11 trial
TovorafenibN/ASmall Molecule1 trial
Active Trials
NCT05760586Approved For Marketing
NCT03429803CompletedEst. Dec 2025
NCT04775485RecruitingEst. May 2027
+1 more trials
FP
Fosun PharmaAustralia - Sydney
1 program
1
LuvometinibPhase 3Small Molecule1 trial
Active Trials
NCT07004075Not Yet Recruiting102Est. Apr 2029
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
ORAL VINORELBINEPhase 21 trial
Active Trials
NCT02197637CompletedEst. Oct 2020
SpringWorks Therapeutics
1 program
1
MirdametinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04923126RecruitingEst. Jun 2031
Ipsen
IpsenChina - Tianjin
1 program
1
TovorafenibPhase 1Small Molecule1 trial
Active Trials
NCT07441707Not Yet Recruiting6Est. Jul 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Fosun PharmaLuvometinib
One BiosciencesTovorafenib
One BiosciencesTovorafenib
Pierre FabreORAL VINORELBINE
SpringWorks TherapeuticsMirdametinib
IpsenTovorafenib
One BiosciencesDAY101

Clinical Trials (8)

Total enrollment: 108 patients across 8 trials

NCT07004075Fosun PharmaLuvometinib

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

Start: Jun 2025Est. completion: Apr 2029102 patients
Phase 3Not Yet Recruiting
NCT05566795One BiosciencesTovorafenib

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Start: Feb 2023Est. completion: Jun 2031
Phase 3Recruiting
NCT04775485One BiosciencesTovorafenib

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Start: Apr 2021Est. completion: May 2027
Phase 2Recruiting
NCT02197637Pierre FabreORAL VINORELBINE

Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma

Start: May 2014Est. completion: Oct 2020
Phase 2Completed
NCT04923126SpringWorks TherapeuticsMirdametinib

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Start: Jun 2021Est. completion: Jun 2031
Phase 1/2Recruiting
NCT07441707IpsenTovorafenib

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

Start: Feb 2026Est. completion: Jul 20306 patients
Phase 1Not Yet Recruiting
NCT03429803One BiosciencesDAY101

DAY101 In Gliomas and Other Tumors

Start: Feb 2018Est. completion: Dec 2025
Phase 1Completed
NCT05760586One BiosciencesTovorafenib

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

N/AApproved For Marketing

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 108 patients
Small Molecule is the dominant modality (100% of programs)
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)